The market for new treatments for “back of the eye” diseases surged in recent years, driven in part by the need to move beyond injections required to be administered every 4-8 weeks. Ocular Therapeutix, Inc. (NASDAQ:OCUL), a nearly 20-year-old company, develops drugs for eye diseases based on its Elutyx bioresorbable hydrogel-based formulation technology. While it has two drugs on the market, the company attracted a $325 million private placement on February 22 based on advancing Axpaxli (axitinib intravitreal implant) to treat wet age-related macular degeneration (wet AMD).
Share this post
SanaCurrents on Ocular's long-term implant to…
Share this post
The market for new treatments for “back of the eye” diseases surged in recent years, driven in part by the need to move beyond injections required to be administered every 4-8 weeks. Ocular Therapeutix, Inc. (NASDAQ:OCUL), a nearly 20-year-old company, develops drugs for eye diseases based on its Elutyx bioresorbable hydrogel-based formulation technology. While it has two drugs on the market, the company attracted a $325 million private placement on February 22 based on advancing Axpaxli (axitinib intravitreal implant) to treat wet age-related macular degeneration (wet AMD).